A ray of hope, but no guarantee the pills will arrive
For the first time in the pandemic, European regulators have opened the door to an oral antiviral treatment for COVID-19, recommending Pfizer's Paxlovid for use across all 27 EU member states. The pill — shown to reduce hospitalizations and deaths by nearly 90 percent in high-risk patients — represents a meaningful shift in how medicine might meet the virus: not in a hospital ward, but at home, early, before the worst unfolds. Yet the distance between a regulatory milestone and a medicine in hand remains vast, and the question of supply reminds us that scientific achievement and human logistics are rarely synchronized.
- Europe's drug regulator has cleared Paxlovid for use across the EU, marking the first oral antiviral approved for COVID-19 on the continent — a landmark in a two-year fight.
- With omicron surging across Europe and hospitalizations straining health systems, the pressure to get effective treatments into patients' hands has never been more acute.
- Pfizer's pill outperforms its closest rival from Merck on both safety and effectiveness, making it the likely frontrunner — but global supply stands at just 180,000 courses, a number dwarfed by demand.
- The EU has regulatory approval but no firm delivery guarantees, prompting the European Parliament's health spokesperson to send an urgent personal appeal directly to Pfizer's CEO.
- Officials warn that the approval is only half the battle — securing timely, sufficient supply requires a separate and ongoing negotiation that remains unresolved.
On Thursday, the European Medicines Agency recommended approval of Pfizer's Paxlovid, making it the first oral antiviral cleared for COVID-19 use across the European Union's 27 member states. The pill is intended for adults at higher risk of severe disease who have not yet required oxygen — the idea being to intervene early, reduce hospitalizations, and keep vulnerable patients out of intensive care. Clinical data showed it reduces hospitalizations and deaths by nearly 90 percent in the most at-risk groups.
Paxlovid arrived with momentum already behind it. U.S. and British regulators had cleared the drug in late December, and a competing pill from Merck is expected to follow soon. But Pfizer's treatment appears poised to become the preferred option, producing only mild side effects while demonstrating stronger effectiveness than its rival. Crucially, neither drug targets the spike protein — the site of omicron's most significant mutations — meaning both are expected to remain effective against the variant now driving surges across Europe and beyond.
The supply picture, however, casts a long shadow over the announcement. Only 180,000 treatment courses exist globally, with 60,000 to 70,000 already allocated to the United States. The EU, home to 450 million people across 27 nations, has yet to secure firm delivery commitments from Pfizer. Peter Liese, the European Parliament's health spokesperson, welcomed the approval as a potential turning point toward normalcy, but warned that neither the European Commission nor member states had guarantees of timely delivery. He disclosed that he had sent an urgent appeal directly to Pfizer's CEO as negotiations over supply continue. The regulatory victory, it turns out, is only the beginning of the work.
On Thursday, the European Medicines Agency took a step that had not been taken before in the pandemic: it recommended approval of an antiviral pill to treat COVID-19. The drug is Pfizer's Paxlovid, and the recommendation clears the way for its use across all 27 nations of the European Union.
The EMA's expert committee determined that the pill should be given to adults who are not yet sick enough to require oxygen but who face a higher risk of developing severe disease. The logic is straightforward: catch the infection early, take the pill, avoid hospitalization. Studies suggest the drug reduces hospitalizations and deaths by nearly 90 percent among the patients most vulnerable to serious illness.
Pfizer's pill arrived at this moment with considerable momentum. U.S. and British regulators had already cleared it in late December, though both noted that supplies would be scarce. A competing antiviral from Merck is also expected to win approval soon, but Paxlovid appears likely to become the preferred choice. The difference comes down to side effects and raw effectiveness. Pfizer's drug produces only mild adverse reactions, while the data on its ability to prevent severe disease outpaced what Merck's pill could demonstrate.
One detail matters for the current moment: both pills are expected to work against omicron, the variant now driving the surge across Europe and much of the world. Neither drug targets the spike protein, where omicron's most troublesome mutations cluster. Laboratory studies suggest Paxlovid will remain active against omicron and other variants that may emerge. The EMA acknowledged that its recommendation was based on trials conducted mostly in people infected with delta, but regulators believed the drug would help contain the omicron wave now underway.
The supply picture, however, tells a different story. Pfizer has 180,000 treatment courses available globally. Of those, roughly 60,000 to 70,000 are allocated to the United States. The company said it expects to have 250,000 courses available in America by month's end, but that still represents a fraction of what would be needed if demand matched the scale of the pandemic. The European Union, with its 27 member states and 450 million people, has not yet secured firm commitments on delivery.
Peter Liese, the European Parliament's health spokesperson, called the regulatory approval a hopeful sign—a potential turning point toward normalcy after two years of pandemic life. But he tempered that optimism with a warning. Neither the European Commission nor individual member states had guarantees that Pfizer would deliver the drug quickly or in the quantities needed. Liese said he had sent an urgent appeal directly to Pfizer's CEO, part of ongoing EU negotiations to secure supply. The approval, in other words, was only half the battle. Getting the pills into the hands of patients would require a separate fight.
Notable Quotes
A real ray of hope for a return to normalcy after the pandemic, but with no guarantees from the European Commission or member countries that the drug would be delivered quickly.— Peter Liese, European Parliament health spokesperson
The Hearth Conversation Another angle on the story
Why does it matter that this is a pill and not an injection or infusion?
Because a pill changes everything about how medicine reaches people. You don't need a clinic, a nurse, a hospital bed. You take it at home. That's the difference between a treatment that reaches thousands and one that reaches millions.
The studies showed 90 percent effectiveness. Against what, exactly?
Against hospitalization and death in people at high risk. Not against infection itself. You can still catch omicron. But if you're older, or immunocompromised, or have other conditions, this pill can keep you out of the hospital.
And the supply problem—is that temporary?
That's the question no one can answer yet. Pfizer says it will ramp up production, but we're talking about a drug that needs to be manufactured, packaged, distributed across 27 countries with different health systems. Even if the company delivers, there will be rationing.
So the approval is almost symbolic?
Not symbolic. Real. But incomplete. You can have the best medicine in the world and it won't help if people can't get it. That's what Liese was saying when he called it a ray of hope but not a guarantee.
What happens if omicron mutates further?
The drug targets parts of the virus that don't change as easily as the spike protein. That's why they think it will work against future variants. But nothing is certain in a pandemic.